drugset / Trial / NCT00736320

HD16 for Early Stage Hodgkin Lymphoma

NCT00736320

Phase 3 Unknown 1150 enrolled University of Cologne
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS).

Timeline

Start
2009-11
Primary completion
2018-09
Completion
2021-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Bleomycin Unknown
Background Dacarbazine Small molecule
Background Doxorubicin Other / unclassified
Background Vincristine Small molecule

Indications